Dasatinib Stimulates Its Own Mechanism of Resistance by Activating a CRTC3/MITF/Bcl-2 Pathway in Melanoma with Mutant or Amplified c-Kit Article Swipe
Malak Sabbah
,
Mohammad Krayem
,
Ahmad Najem
,
François Salès
,
Wilson H. Miller
,
Sonia V. del Rincón
,
Ahmad Awada
,
Ghanem E. Ghanem
,
Fabrice Journé
·
YOU?
·
· 2021
· Open Access
·
· DOI: https://doi.org/10.1158/1541-7786.mcr-20-1040
YOU?
·
· 2021
· Open Access
·
· DOI: https://doi.org/10.1158/1541-7786.mcr-20-1040
Amplification or activating mutations of c-Kit are a frequent oncogenic alteration, which occurs commonly in acral and mucosal melanoma. Among c-Kit inhibitors, dasatinib is the most active due to its ability to bind both active and inactive conformations of the receptor. However, its use as a single agent in melanoma showed limited clinical benefit. We first found that sensitivity to dasatinib is restricted to melanoma cell lines harboring c-Kit alteration but, unexpectedly, we observed lower effect at higher concentrations that can readily be found in patient blood. We then investigated relevant pathway alterations and found complete inhibition of MAPK and PI3K/AKT pathways but an increase in MITF and its downstream target Bcl-2 through CRTC3 pathway, which turn on the CREB regulated transcription of MITF. More importantly, dasatinib upregulates MITF and Bcl-2 through SIK2 inhibition revealed by CRTC3 reduced phosphorylation, CREB transcription activation of MITF, MITF transcription activation of Bcl-2 as well as pigmentation. Furthermore, overexpression of MITF renders melanoma cells resistant to all dasatinib concentrations. Selective Bcl-2 inhibition by ABT-199 or Bcl-2 knockout restores the sensitivity of melanoma cells to dasatinib, validating the involvement of MITF and Bcl-2 axis in the resistance of melanoma to dasatinib. In conclusion, we showed for the first time that dasatinib in melanoma stimulates its proper mechanism of resistance, independently of MAPK and PI3K/AKT pathways reactivation commonly associated to secondary c-Kit mutations, but through CRTC3/MITF/Bcl-2 pathway activation at clinically relevant doses which may explain the weak clinical benefit of dasatinib in patients with melanoma. Implications: Dasatinib stimulates its proper mechanism of resistance through CRTC3/MITF/Bcl-2 pathway, which may explain its modest clinical efficiency in patients with melanoma.
Related Topics
Concepts
Microphthalmia-associated transcription factor
Dasatinib
Melanoma
Cancer research
CREB
MAPK/ERK pathway
PI3K/AKT/mTOR pathway
Protein kinase B
Transcription factor
Kinase
Phosphorylation
Biology
Chemistry
Signal transduction
Cell biology
Gene
Biochemistry
Imatinib
Myeloid leukemia
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1158/1541-7786.mcr-20-1040
- https://aacrjournals.org/mcr/article-pdf/19/7/1221/3058268/1221.pdf
- OA Status
- bronze
- Cited By
- 6
- References
- 56
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W3137568497
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W3137568497Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1158/1541-7786.mcr-20-1040Digital Object Identifier
- Title
-
Dasatinib Stimulates Its Own Mechanism of Resistance by Activating a CRTC3/MITF/Bcl-2 Pathway in Melanoma with Mutant or Amplified c-KitWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2021Year of publication
- Publication date
-
2021-03-19Full publication date if available
- Authors
-
Malak Sabbah, Mohammad Krayem, Ahmad Najem, François Salès, Wilson H. Miller, Sonia V. del Rincón, Ahmad Awada, Ghanem E. Ghanem, Fabrice JournéList of authors in order
- Landing page
-
https://doi.org/10.1158/1541-7786.mcr-20-1040Publisher landing page
- PDF URL
-
https://aacrjournals.org/mcr/article-pdf/19/7/1221/3058268/1221.pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
bronzeOpen access status per OpenAlex
- OA URL
-
https://aacrjournals.org/mcr/article-pdf/19/7/1221/3058268/1221.pdfDirect OA link when available
- Concepts
-
Microphthalmia-associated transcription factor, Dasatinib, Melanoma, Cancer research, CREB, MAPK/ERK pathway, PI3K/AKT/mTOR pathway, Protein kinase B, Transcription factor, Kinase, Phosphorylation, Biology, Chemistry, Signal transduction, Cell biology, Gene, Biochemistry, Imatinib, Myeloid leukemiaTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
6Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 2, 2023: 2, 2022: 2Per-year citation counts (last 5 years)
- References (count)
-
56Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W3137568497 |
|---|---|
| doi | https://doi.org/10.1158/1541-7786.mcr-20-1040 |
| ids.doi | https://doi.org/10.1158/1541-7786.mcr-20-1040 |
| ids.mag | 3137568497 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/33741716 |
| ids.openalex | https://openalex.org/W3137568497 |
| fwci | 0.41288612 |
| mesh[0].qualifier_ui | Q000494 |
| mesh[0].descriptor_ui | D000970 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | pharmacology |
| mesh[0].descriptor_name | Antineoplastic Agents |
| mesh[1].qualifier_ui | Q000187 |
| mesh[1].descriptor_ui | D017209 |
| mesh[1].is_major_topic | False |
| mesh[1].qualifier_name | drug effects |
| mesh[1].descriptor_name | Apoptosis |
| mesh[2].qualifier_ui | Q000235 |
| mesh[2].descriptor_ui | D017209 |
| mesh[2].is_major_topic | False |
| mesh[2].qualifier_name | genetics |
| mesh[2].descriptor_name | Apoptosis |
| mesh[3].qualifier_ui | |
| mesh[3].descriptor_ui | D045744 |
| mesh[3].is_major_topic | False |
| mesh[3].qualifier_name | |
| mesh[3].descriptor_name | Cell Line, Tumor |
| mesh[4].qualifier_ui | Q000187 |
| mesh[4].descriptor_ui | D049109 |
| mesh[4].is_major_topic | False |
| mesh[4].qualifier_name | drug effects |
| mesh[4].descriptor_name | Cell Proliferation |
| mesh[5].qualifier_ui | Q000235 |
| mesh[5].descriptor_ui | D049109 |
| mesh[5].is_major_topic | False |
| mesh[5].qualifier_name | genetics |
| mesh[5].descriptor_name | Cell Proliferation |
| mesh[6].qualifier_ui | Q000494 |
| mesh[6].descriptor_ui | D000069439 |
| mesh[6].is_major_topic | False |
| mesh[6].qualifier_name | pharmacology |
| mesh[6].descriptor_name | Dasatinib |
| mesh[7].qualifier_ui | Q000187 |
| mesh[7].descriptor_ui | D019008 |
| mesh[7].is_major_topic | False |
| mesh[7].qualifier_name | drug effects |
| mesh[7].descriptor_name | Drug Resistance, Neoplasm |
| mesh[8].qualifier_ui | Q000235 |
| mesh[8].descriptor_ui | D019008 |
| mesh[8].is_major_topic | False |
| mesh[8].qualifier_name | genetics |
| mesh[8].descriptor_name | Drug Resistance, Neoplasm |
| mesh[9].qualifier_ui | |
| mesh[9].descriptor_ui | D005784 |
| mesh[9].is_major_topic | False |
| mesh[9].qualifier_name | |
| mesh[9].descriptor_name | Gene Amplification |
| mesh[10].qualifier_ui | Q000187 |
| mesh[10].descriptor_ui | D015972 |
| mesh[10].is_major_topic | False |
| mesh[10].qualifier_name | drug effects |
| mesh[10].descriptor_name | Gene Expression Regulation, Neoplastic |
| mesh[11].qualifier_ui | |
| mesh[11].descriptor_ui | D006801 |
| mesh[11].is_major_topic | False |
| mesh[11].qualifier_name | |
| mesh[11].descriptor_name | Humans |
| mesh[12].qualifier_ui | Q000235 |
| mesh[12].descriptor_ui | D008545 |
| mesh[12].is_major_topic | False |
| mesh[12].qualifier_name | genetics |
| mesh[12].descriptor_name | Melanoma |
| mesh[13].qualifier_ui | Q000378 |
| mesh[13].descriptor_ui | D008545 |
| mesh[13].is_major_topic | False |
| mesh[13].qualifier_name | metabolism |
| mesh[13].descriptor_name | Melanoma |
| mesh[14].qualifier_ui | Q000473 |
| mesh[14].descriptor_ui | D008545 |
| mesh[14].is_major_topic | False |
| mesh[14].qualifier_name | pathology |
| mesh[14].descriptor_name | Melanoma |
| mesh[15].qualifier_ui | Q000235 |
| mesh[15].descriptor_ui | D051739 |
| mesh[15].is_major_topic | False |
| mesh[15].qualifier_name | genetics |
| mesh[15].descriptor_name | Microphthalmia-Associated Transcription Factor |
| mesh[16].qualifier_ui | Q000378 |
| mesh[16].descriptor_ui | D051739 |
| mesh[16].is_major_topic | False |
| mesh[16].qualifier_name | metabolism |
| mesh[16].descriptor_name | Microphthalmia-Associated Transcription Factor |
| mesh[17].qualifier_ui | |
| mesh[17].descriptor_ui | D009154 |
| mesh[17].is_major_topic | False |
| mesh[17].qualifier_name | |
| mesh[17].descriptor_name | Mutation |
| mesh[18].qualifier_ui | Q000235 |
| mesh[18].descriptor_ui | D011506 |
| mesh[18].is_major_topic | False |
| mesh[18].qualifier_name | genetics |
| mesh[18].descriptor_name | Proteins |
| mesh[19].qualifier_ui | Q000378 |
| mesh[19].descriptor_ui | D011506 |
| mesh[19].is_major_topic | False |
| mesh[19].qualifier_name | metabolism |
| mesh[19].descriptor_name | Proteins |
| mesh[20].qualifier_ui | Q000235 |
| mesh[20].descriptor_ui | D019253 |
| mesh[20].is_major_topic | False |
| mesh[20].qualifier_name | genetics |
| mesh[20].descriptor_name | Proto-Oncogene Proteins c-bcl-2 |
| mesh[21].qualifier_ui | Q000378 |
| mesh[21].descriptor_ui | D019253 |
| mesh[21].is_major_topic | False |
| mesh[21].qualifier_name | metabolism |
| mesh[21].descriptor_name | Proto-Oncogene Proteins c-bcl-2 |
| mesh[22].qualifier_ui | Q000235 |
| mesh[22].descriptor_ui | D019009 |
| mesh[22].is_major_topic | False |
| mesh[22].qualifier_name | genetics |
| mesh[22].descriptor_name | Proto-Oncogene Proteins c-kit |
| mesh[23].qualifier_ui | Q000378 |
| mesh[23].descriptor_ui | D019009 |
| mesh[23].is_major_topic | False |
| mesh[23].qualifier_name | metabolism |
| mesh[23].descriptor_name | Proto-Oncogene Proteins c-kit |
| mesh[24].qualifier_ui | Q000187 |
| mesh[24].descriptor_ui | D015398 |
| mesh[24].is_major_topic | False |
| mesh[24].qualifier_name | drug effects |
| mesh[24].descriptor_name | Signal Transduction |
| mesh[25].qualifier_ui | Q000235 |
| mesh[25].descriptor_ui | D015398 |
| mesh[25].is_major_topic | False |
| mesh[25].qualifier_name | genetics |
| mesh[25].descriptor_name | Signal Transduction |
| mesh[26].qualifier_ui | Q000235 |
| mesh[26].descriptor_ui | D014157 |
| mesh[26].is_major_topic | False |
| mesh[26].qualifier_name | genetics |
| mesh[26].descriptor_name | Transcription Factors |
| mesh[27].qualifier_ui | Q000378 |
| mesh[27].descriptor_ui | D014157 |
| mesh[27].is_major_topic | False |
| mesh[27].qualifier_name | metabolism |
| mesh[27].descriptor_name | Transcription Factors |
| mesh[28].qualifier_ui | Q000494 |
| mesh[28].descriptor_ui | D000970 |
| mesh[28].is_major_topic | False |
| mesh[28].qualifier_name | pharmacology |
| mesh[28].descriptor_name | Antineoplastic Agents |
| mesh[29].qualifier_ui | Q000187 |
| mesh[29].descriptor_ui | D017209 |
| mesh[29].is_major_topic | False |
| mesh[29].qualifier_name | drug effects |
| mesh[29].descriptor_name | Apoptosis |
| mesh[30].qualifier_ui | Q000235 |
| mesh[30].descriptor_ui | D017209 |
| mesh[30].is_major_topic | False |
| mesh[30].qualifier_name | genetics |
| mesh[30].descriptor_name | Apoptosis |
| mesh[31].qualifier_ui | |
| mesh[31].descriptor_ui | D045744 |
| mesh[31].is_major_topic | False |
| mesh[31].qualifier_name | |
| mesh[31].descriptor_name | Cell Line, Tumor |
| mesh[32].qualifier_ui | Q000187 |
| mesh[32].descriptor_ui | D049109 |
| mesh[32].is_major_topic | False |
| mesh[32].qualifier_name | drug effects |
| mesh[32].descriptor_name | Cell Proliferation |
| mesh[33].qualifier_ui | Q000235 |
| mesh[33].descriptor_ui | D049109 |
| mesh[33].is_major_topic | False |
| mesh[33].qualifier_name | genetics |
| mesh[33].descriptor_name | Cell Proliferation |
| mesh[34].qualifier_ui | Q000494 |
| mesh[34].descriptor_ui | D000069439 |
| mesh[34].is_major_topic | False |
| mesh[34].qualifier_name | pharmacology |
| mesh[34].descriptor_name | Dasatinib |
| mesh[35].qualifier_ui | Q000187 |
| mesh[35].descriptor_ui | D019008 |
| mesh[35].is_major_topic | False |
| mesh[35].qualifier_name | drug effects |
| mesh[35].descriptor_name | Drug Resistance, Neoplasm |
| mesh[36].qualifier_ui | Q000235 |
| mesh[36].descriptor_ui | D019008 |
| mesh[36].is_major_topic | False |
| mesh[36].qualifier_name | genetics |
| mesh[36].descriptor_name | Drug Resistance, Neoplasm |
| mesh[37].qualifier_ui | |
| mesh[37].descriptor_ui | D005784 |
| mesh[37].is_major_topic | False |
| mesh[37].qualifier_name | |
| mesh[37].descriptor_name | Gene Amplification |
| mesh[38].qualifier_ui | Q000187 |
| mesh[38].descriptor_ui | D015972 |
| mesh[38].is_major_topic | False |
| mesh[38].qualifier_name | drug effects |
| mesh[38].descriptor_name | Gene Expression Regulation, Neoplastic |
| mesh[39].qualifier_ui | |
| mesh[39].descriptor_ui | D006801 |
| mesh[39].is_major_topic | False |
| mesh[39].qualifier_name | |
| mesh[39].descriptor_name | Humans |
| mesh[40].qualifier_ui | Q000235 |
| mesh[40].descriptor_ui | D008545 |
| mesh[40].is_major_topic | False |
| mesh[40].qualifier_name | genetics |
| mesh[40].descriptor_name | Melanoma |
| mesh[41].qualifier_ui | Q000378 |
| mesh[41].descriptor_ui | D008545 |
| mesh[41].is_major_topic | False |
| mesh[41].qualifier_name | metabolism |
| mesh[41].descriptor_name | Melanoma |
| mesh[42].qualifier_ui | Q000473 |
| mesh[42].descriptor_ui | D008545 |
| mesh[42].is_major_topic | False |
| mesh[42].qualifier_name | pathology |
| mesh[42].descriptor_name | Melanoma |
| mesh[43].qualifier_ui | Q000235 |
| mesh[43].descriptor_ui | D051739 |
| mesh[43].is_major_topic | False |
| mesh[43].qualifier_name | genetics |
| mesh[43].descriptor_name | Microphthalmia-Associated Transcription Factor |
| mesh[44].qualifier_ui | Q000378 |
| mesh[44].descriptor_ui | D051739 |
| mesh[44].is_major_topic | False |
| mesh[44].qualifier_name | metabolism |
| mesh[44].descriptor_name | Microphthalmia-Associated Transcription Factor |
| mesh[45].qualifier_ui | |
| mesh[45].descriptor_ui | D009154 |
| mesh[45].is_major_topic | False |
| mesh[45].qualifier_name | |
| mesh[45].descriptor_name | Mutation |
| mesh[46].qualifier_ui | Q000235 |
| mesh[46].descriptor_ui | D011506 |
| mesh[46].is_major_topic | False |
| mesh[46].qualifier_name | genetics |
| mesh[46].descriptor_name | Proteins |
| mesh[47].qualifier_ui | Q000378 |
| mesh[47].descriptor_ui | D011506 |
| mesh[47].is_major_topic | False |
| mesh[47].qualifier_name | metabolism |
| mesh[47].descriptor_name | Proteins |
| mesh[48].qualifier_ui | Q000235 |
| mesh[48].descriptor_ui | D019253 |
| mesh[48].is_major_topic | False |
| mesh[48].qualifier_name | genetics |
| mesh[48].descriptor_name | Proto-Oncogene Proteins c-bcl-2 |
| mesh[49].qualifier_ui | Q000378 |
| mesh[49].descriptor_ui | D019253 |
| mesh[49].is_major_topic | False |
| mesh[49].qualifier_name | metabolism |
| mesh[49].descriptor_name | Proto-Oncogene Proteins c-bcl-2 |
| type | article |
| title | Dasatinib Stimulates Its Own Mechanism of Resistance by Activating a CRTC3/MITF/Bcl-2 Pathway in Melanoma with Mutant or Amplified c-Kit |
| biblio.issue | 7 |
| biblio.volume | 19 |
| biblio.last_page | 1233 |
| biblio.first_page | 1221 |
| grants[0].funder | https://openalex.org/F4320326734 |
| grants[0].award_id | |
| grants[0].funder_display_name | Wallonie-Bruxelles International |
| topics[0].id | https://openalex.org/T11346 |
| topics[0].field.id | https://openalex.org/fields/24 |
| topics[0].field.display_name | Immunology and Microbiology |
| topics[0].score | 0.9997000098228455 |
| topics[0].domain.id | https://openalex.org/domains/1 |
| topics[0].domain.display_name | Life Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2403 |
| topics[0].subfield.display_name | Immunology |
| topics[0].display_name | Mast cells and histamine |
| topics[1].id | https://openalex.org/T11533 |
| topics[1].field.id | https://openalex.org/fields/13 |
| topics[1].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[1].score | 0.9961000084877014 |
| topics[1].domain.id | https://openalex.org/domains/1 |
| topics[1].domain.display_name | Life Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/1312 |
| topics[1].subfield.display_name | Molecular Biology |
| topics[1].display_name | Melanoma and MAPK Pathways |
| topics[2].id | https://openalex.org/T10952 |
| topics[2].field.id | https://openalex.org/fields/13 |
| topics[2].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[2].score | 0.993399977684021 |
| topics[2].domain.id | https://openalex.org/domains/1 |
| topics[2].domain.display_name | Life Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/1312 |
| topics[2].subfield.display_name | Molecular Biology |
| topics[2].display_name | PI3K/AKT/mTOR signaling in cancer |
| funders[0].id | https://openalex.org/F4320326734 |
| funders[0].ror | https://ror.org/008vsyy18 |
| funders[0].display_name | Wallonie-Bruxelles International |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C177504595 |
| concepts[0].level | 4 |
| concepts[0].score | 0.985112190246582 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q336500 |
| concepts[0].display_name | Microphthalmia-associated transcription factor |
| concepts[1].id | https://openalex.org/C2779536868 |
| concepts[1].level | 4 |
| concepts[1].score | 0.9163281917572021 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q419940 |
| concepts[1].display_name | Dasatinib |
| concepts[2].id | https://openalex.org/C2777658100 |
| concepts[2].level | 2 |
| concepts[2].score | 0.6706030368804932 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q180614 |
| concepts[2].display_name | Melanoma |
| concepts[3].id | https://openalex.org/C502942594 |
| concepts[3].level | 1 |
| concepts[3].score | 0.6677919626235962 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q3421914 |
| concepts[3].display_name | Cancer research |
| concepts[4].id | https://openalex.org/C1629964 |
| concepts[4].level | 4 |
| concepts[4].score | 0.6015192270278931 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q106950729 |
| concepts[4].display_name | CREB |
| concepts[5].id | https://openalex.org/C57074206 |
| concepts[5].level | 3 |
| concepts[5].score | 0.5847230553627014 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q14197552 |
| concepts[5].display_name | MAPK/ERK pathway |
| concepts[6].id | https://openalex.org/C86554907 |
| concepts[6].level | 3 |
| concepts[6].score | 0.48790308833122253 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q285613 |
| concepts[6].display_name | PI3K/AKT/mTOR pathway |
| concepts[7].id | https://openalex.org/C75217442 |
| concepts[7].level | 3 |
| concepts[7].score | 0.4466547667980194 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q423650 |
| concepts[7].display_name | Protein kinase B |
| concepts[8].id | https://openalex.org/C86339819 |
| concepts[8].level | 3 |
| concepts[8].score | 0.44645723700523376 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q407384 |
| concepts[8].display_name | Transcription factor |
| concepts[9].id | https://openalex.org/C184235292 |
| concepts[9].level | 2 |
| concepts[9].score | 0.41489261388778687 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q421851 |
| concepts[9].display_name | Kinase |
| concepts[10].id | https://openalex.org/C11960822 |
| concepts[10].level | 2 |
| concepts[10].score | 0.4124906659126282 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q242736 |
| concepts[10].display_name | Phosphorylation |
| concepts[11].id | https://openalex.org/C86803240 |
| concepts[11].level | 0 |
| concepts[11].score | 0.3985404074192047 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q420 |
| concepts[11].display_name | Biology |
| concepts[12].id | https://openalex.org/C185592680 |
| concepts[12].level | 0 |
| concepts[12].score | 0.343183308839798 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q2329 |
| concepts[12].display_name | Chemistry |
| concepts[13].id | https://openalex.org/C62478195 |
| concepts[13].level | 2 |
| concepts[13].score | 0.31575143337249756 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q828130 |
| concepts[13].display_name | Signal transduction |
| concepts[14].id | https://openalex.org/C95444343 |
| concepts[14].level | 1 |
| concepts[14].score | 0.17054146528244019 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q7141 |
| concepts[14].display_name | Cell biology |
| concepts[15].id | https://openalex.org/C104317684 |
| concepts[15].level | 2 |
| concepts[15].score | 0.08042511343955994 |
| concepts[15].wikidata | https://www.wikidata.org/wiki/Q7187 |
| concepts[15].display_name | Gene |
| concepts[16].id | https://openalex.org/C55493867 |
| concepts[16].level | 1 |
| concepts[16].score | 0.07650849223136902 |
| concepts[16].wikidata | https://www.wikidata.org/wiki/Q7094 |
| concepts[16].display_name | Biochemistry |
| concepts[17].id | https://openalex.org/C2777583451 |
| concepts[17].level | 3 |
| concepts[17].score | 0.0 |
| concepts[17].wikidata | https://www.wikidata.org/wiki/Q177094 |
| concepts[17].display_name | Imatinib |
| concepts[18].id | https://openalex.org/C2778729363 |
| concepts[18].level | 2 |
| concepts[18].score | 0.0 |
| concepts[18].wikidata | https://www.wikidata.org/wiki/Q11688946 |
| concepts[18].display_name | Myeloid leukemia |
| keywords[0].id | https://openalex.org/keywords/microphthalmia-associated-transcription-factor |
| keywords[0].score | 0.985112190246582 |
| keywords[0].display_name | Microphthalmia-associated transcription factor |
| keywords[1].id | https://openalex.org/keywords/dasatinib |
| keywords[1].score | 0.9163281917572021 |
| keywords[1].display_name | Dasatinib |
| keywords[2].id | https://openalex.org/keywords/melanoma |
| keywords[2].score | 0.6706030368804932 |
| keywords[2].display_name | Melanoma |
| keywords[3].id | https://openalex.org/keywords/cancer-research |
| keywords[3].score | 0.6677919626235962 |
| keywords[3].display_name | Cancer research |
| keywords[4].id | https://openalex.org/keywords/creb |
| keywords[4].score | 0.6015192270278931 |
| keywords[4].display_name | CREB |
| keywords[5].id | https://openalex.org/keywords/mapk/erk-pathway |
| keywords[5].score | 0.5847230553627014 |
| keywords[5].display_name | MAPK/ERK pathway |
| keywords[6].id | https://openalex.org/keywords/pi3k/akt/mtor-pathway |
| keywords[6].score | 0.48790308833122253 |
| keywords[6].display_name | PI3K/AKT/mTOR pathway |
| keywords[7].id | https://openalex.org/keywords/protein-kinase-b |
| keywords[7].score | 0.4466547667980194 |
| keywords[7].display_name | Protein kinase B |
| keywords[8].id | https://openalex.org/keywords/transcription-factor |
| keywords[8].score | 0.44645723700523376 |
| keywords[8].display_name | Transcription factor |
| keywords[9].id | https://openalex.org/keywords/kinase |
| keywords[9].score | 0.41489261388778687 |
| keywords[9].display_name | Kinase |
| keywords[10].id | https://openalex.org/keywords/phosphorylation |
| keywords[10].score | 0.4124906659126282 |
| keywords[10].display_name | Phosphorylation |
| keywords[11].id | https://openalex.org/keywords/biology |
| keywords[11].score | 0.3985404074192047 |
| keywords[11].display_name | Biology |
| keywords[12].id | https://openalex.org/keywords/chemistry |
| keywords[12].score | 0.343183308839798 |
| keywords[12].display_name | Chemistry |
| keywords[13].id | https://openalex.org/keywords/signal-transduction |
| keywords[13].score | 0.31575143337249756 |
| keywords[13].display_name | Signal transduction |
| keywords[14].id | https://openalex.org/keywords/cell-biology |
| keywords[14].score | 0.17054146528244019 |
| keywords[14].display_name | Cell biology |
| keywords[15].id | https://openalex.org/keywords/gene |
| keywords[15].score | 0.08042511343955994 |
| keywords[15].display_name | Gene |
| keywords[16].id | https://openalex.org/keywords/biochemistry |
| keywords[16].score | 0.07650849223136902 |
| keywords[16].display_name | Biochemistry |
| language | en |
| locations[0].id | doi:10.1158/1541-7786.mcr-20-1040 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S192067876 |
| locations[0].source.issn | 1541-7786, 1557-3125 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 1541-7786 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Molecular Cancer Research |
| locations[0].source.host_organization | https://openalex.org/P4310320273 |
| locations[0].source.host_organization_name | American Association for Cancer Research |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320273 |
| locations[0].license | |
| locations[0].pdf_url | https://aacrjournals.org/mcr/article-pdf/19/7/1221/3058268/1221.pdf |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Molecular Cancer Research |
| locations[0].landing_page_url | https://doi.org/10.1158/1541-7786.mcr-20-1040 |
| locations[1].id | pmid:33741716 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Molecular cancer research : MCR |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/33741716 |
| locations[2].id | pmh:oai:dipot.ulb.ac.be:2013/329185 |
| locations[2].is_oa | True |
| locations[2].source.id | https://openalex.org/S4306401063 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) |
| locations[2].source.host_organization | https://openalex.org/I132053463 |
| locations[2].source.host_organization_name | Université Libre de Bruxelles |
| locations[2].source.host_organization_lineage | https://openalex.org/I132053463 |
| locations[2].license | other-oa |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | info:eu-repo/semantics/article |
| locations[2].license_id | https://openalex.org/licenses/other-oa |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | Molecular cancer research, 19 (7 |
| locations[2].landing_page_url | http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/329185 |
| indexed_in | crossref, pubmed |
| authorships[0].author.id | https://openalex.org/A5037892686 |
| authorships[0].author.orcid | https://orcid.org/0000-0001-7074-8143 |
| authorships[0].author.display_name | Malak Sabbah |
| authorships[0].countries | BE |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I132053463, https://openalex.org/I2801838318 |
| authorships[0].affiliations[0].raw_affiliation_string | 1Laboratory of Oncology and Experimental Surgery, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. |
| authorships[0].institutions[0].id | https://openalex.org/I2801838318 |
| authorships[0].institutions[0].ror | https://ror.org/05e8s8534 |
| authorships[0].institutions[0].type | healthcare |
| authorships[0].institutions[0].lineage | https://openalex.org/I2801838318 |
| authorships[0].institutions[0].country_code | BE |
| authorships[0].institutions[0].display_name | Institut Jules Bordet |
| authorships[0].institutions[1].id | https://openalex.org/I132053463 |
| authorships[0].institutions[1].ror | https://ror.org/01r9htc13 |
| authorships[0].institutions[1].type | education |
| authorships[0].institutions[1].lineage | https://openalex.org/I132053463 |
| authorships[0].institutions[1].country_code | BE |
| authorships[0].institutions[1].display_name | Université Libre de Bruxelles |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Malak Sabbah |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | 1Laboratory of Oncology and Experimental Surgery, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. |
| authorships[1].author.id | https://openalex.org/A5091892350 |
| authorships[1].author.orcid | https://orcid.org/0000-0003-3969-3687 |
| authorships[1].author.display_name | Mohammad Krayem |
| authorships[1].countries | BE |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I132053463, https://openalex.org/I2801838318 |
| authorships[1].affiliations[0].raw_affiliation_string | 1Laboratory of Oncology and Experimental Surgery, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. |
| authorships[1].institutions[0].id | https://openalex.org/I2801838318 |
| authorships[1].institutions[0].ror | https://ror.org/05e8s8534 |
| authorships[1].institutions[0].type | healthcare |
| authorships[1].institutions[0].lineage | https://openalex.org/I2801838318 |
| authorships[1].institutions[0].country_code | BE |
| authorships[1].institutions[0].display_name | Institut Jules Bordet |
| authorships[1].institutions[1].id | https://openalex.org/I132053463 |
| authorships[1].institutions[1].ror | https://ror.org/01r9htc13 |
| authorships[1].institutions[1].type | education |
| authorships[1].institutions[1].lineage | https://openalex.org/I132053463 |
| authorships[1].institutions[1].country_code | BE |
| authorships[1].institutions[1].display_name | Université Libre de Bruxelles |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Mohammad Krayem |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | 1Laboratory of Oncology and Experimental Surgery, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. |
| authorships[2].author.id | https://openalex.org/A5057255038 |
| authorships[2].author.orcid | https://orcid.org/0000-0003-0631-0029 |
| authorships[2].author.display_name | Ahmad Najem |
| authorships[2].countries | BE |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I132053463, https://openalex.org/I2801838318 |
| authorships[2].affiliations[0].raw_affiliation_string | 1Laboratory of Oncology and Experimental Surgery, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. |
| authorships[2].institutions[0].id | https://openalex.org/I2801838318 |
| authorships[2].institutions[0].ror | https://ror.org/05e8s8534 |
| authorships[2].institutions[0].type | healthcare |
| authorships[2].institutions[0].lineage | https://openalex.org/I2801838318 |
| authorships[2].institutions[0].country_code | BE |
| authorships[2].institutions[0].display_name | Institut Jules Bordet |
| authorships[2].institutions[1].id | https://openalex.org/I132053463 |
| authorships[2].institutions[1].ror | https://ror.org/01r9htc13 |
| authorships[2].institutions[1].type | education |
| authorships[2].institutions[1].lineage | https://openalex.org/I132053463 |
| authorships[2].institutions[1].country_code | BE |
| authorships[2].institutions[1].display_name | Université Libre de Bruxelles |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Ahmad Najem |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | 1Laboratory of Oncology and Experimental Surgery, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. |
| authorships[3].author.id | https://openalex.org/A5088550663 |
| authorships[3].author.orcid | https://orcid.org/0000-0003-0307-5596 |
| authorships[3].author.display_name | François Salès |
| authorships[3].countries | BE |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I132053463, https://openalex.org/I2801838318 |
| authorships[3].affiliations[0].raw_affiliation_string | 1Laboratory of Oncology and Experimental Surgery, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. |
| authorships[3].institutions[0].id | https://openalex.org/I2801838318 |
| authorships[3].institutions[0].ror | https://ror.org/05e8s8534 |
| authorships[3].institutions[0].type | healthcare |
| authorships[3].institutions[0].lineage | https://openalex.org/I2801838318 |
| authorships[3].institutions[0].country_code | BE |
| authorships[3].institutions[0].display_name | Institut Jules Bordet |
| authorships[3].institutions[1].id | https://openalex.org/I132053463 |
| authorships[3].institutions[1].ror | https://ror.org/01r9htc13 |
| authorships[3].institutions[1].type | education |
| authorships[3].institutions[1].lineage | https://openalex.org/I132053463 |
| authorships[3].institutions[1].country_code | BE |
| authorships[3].institutions[1].display_name | Université Libre de Bruxelles |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | François Sales |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | 1Laboratory of Oncology and Experimental Surgery, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. |
| authorships[4].author.id | https://openalex.org/A5048013287 |
| authorships[4].author.orcid | https://orcid.org/0000-0002-7408-1574 |
| authorships[4].author.display_name | Wilson H. Miller |
| authorships[4].countries | CA |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I2801824472, https://openalex.org/I5023651 |
| authorships[4].affiliations[0].raw_affiliation_string | 2Segal Cancer Centre, Lady Davis Institute, Jewish General Hospital, McGill University, Montreal, QC, Canada. |
| authorships[4].institutions[0].id | https://openalex.org/I2801824472 |
| authorships[4].institutions[0].ror | https://ror.org/056jjra10 |
| authorships[4].institutions[0].type | healthcare |
| authorships[4].institutions[0].lineage | https://openalex.org/I2801824472 |
| authorships[4].institutions[0].country_code | CA |
| authorships[4].institutions[0].display_name | Jewish General Hospital |
| authorships[4].institutions[1].id | https://openalex.org/I5023651 |
| authorships[4].institutions[1].ror | https://ror.org/01pxwe438 |
| authorships[4].institutions[1].type | education |
| authorships[4].institutions[1].lineage | https://openalex.org/I5023651 |
| authorships[4].institutions[1].country_code | CA |
| authorships[4].institutions[1].display_name | McGill University |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Wilson Miller |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | 2Segal Cancer Centre, Lady Davis Institute, Jewish General Hospital, McGill University, Montreal, QC, Canada. |
| authorships[5].author.id | https://openalex.org/A5089111286 |
| authorships[5].author.orcid | https://orcid.org/0000-0002-6350-0227 |
| authorships[5].author.display_name | Sonia V. del Rincón |
| authorships[5].countries | CA |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I2801824472, https://openalex.org/I5023651 |
| authorships[5].affiliations[0].raw_affiliation_string | 2Segal Cancer Centre, Lady Davis Institute, Jewish General Hospital, McGill University, Montreal, QC, Canada. |
| authorships[5].institutions[0].id | https://openalex.org/I2801824472 |
| authorships[5].institutions[0].ror | https://ror.org/056jjra10 |
| authorships[5].institutions[0].type | healthcare |
| authorships[5].institutions[0].lineage | https://openalex.org/I2801824472 |
| authorships[5].institutions[0].country_code | CA |
| authorships[5].institutions[0].display_name | Jewish General Hospital |
| authorships[5].institutions[1].id | https://openalex.org/I5023651 |
| authorships[5].institutions[1].ror | https://ror.org/01pxwe438 |
| authorships[5].institutions[1].type | education |
| authorships[5].institutions[1].lineage | https://openalex.org/I5023651 |
| authorships[5].institutions[1].country_code | CA |
| authorships[5].institutions[1].display_name | McGill University |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Sonia del Rincon |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | 2Segal Cancer Centre, Lady Davis Institute, Jewish General Hospital, McGill University, Montreal, QC, Canada. |
| authorships[6].author.id | https://openalex.org/A5010064853 |
| authorships[6].author.orcid | |
| authorships[6].author.display_name | Ahmad Awada |
| authorships[6].countries | BE |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I132053463, https://openalex.org/I2801838318 |
| authorships[6].affiliations[0].raw_affiliation_string | 3Medical Oncolgy Clinic, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. |
| authorships[6].institutions[0].id | https://openalex.org/I2801838318 |
| authorships[6].institutions[0].ror | https://ror.org/05e8s8534 |
| authorships[6].institutions[0].type | healthcare |
| authorships[6].institutions[0].lineage | https://openalex.org/I2801838318 |
| authorships[6].institutions[0].country_code | BE |
| authorships[6].institutions[0].display_name | Institut Jules Bordet |
| authorships[6].institutions[1].id | https://openalex.org/I132053463 |
| authorships[6].institutions[1].ror | https://ror.org/01r9htc13 |
| authorships[6].institutions[1].type | education |
| authorships[6].institutions[1].lineage | https://openalex.org/I132053463 |
| authorships[6].institutions[1].country_code | BE |
| authorships[6].institutions[1].display_name | Université Libre de Bruxelles |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Ahmad Awada |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | 3Medical Oncolgy Clinic, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. |
| authorships[7].author.id | https://openalex.org/A5017607911 |
| authorships[7].author.orcid | |
| authorships[7].author.display_name | Ghanem E. Ghanem |
| authorships[7].countries | BE |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I132053463, https://openalex.org/I2801838318 |
| authorships[7].affiliations[0].raw_affiliation_string | 1Laboratory of Oncology and Experimental Surgery, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. |
| authorships[7].institutions[0].id | https://openalex.org/I2801838318 |
| authorships[7].institutions[0].ror | https://ror.org/05e8s8534 |
| authorships[7].institutions[0].type | healthcare |
| authorships[7].institutions[0].lineage | https://openalex.org/I2801838318 |
| authorships[7].institutions[0].country_code | BE |
| authorships[7].institutions[0].display_name | Institut Jules Bordet |
| authorships[7].institutions[1].id | https://openalex.org/I132053463 |
| authorships[7].institutions[1].ror | https://ror.org/01r9htc13 |
| authorships[7].institutions[1].type | education |
| authorships[7].institutions[1].lineage | https://openalex.org/I132053463 |
| authorships[7].institutions[1].country_code | BE |
| authorships[7].institutions[1].display_name | Université Libre de Bruxelles |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Ghanem E. Ghanem |
| authorships[7].is_corresponding | True |
| authorships[7].raw_affiliation_strings | 1Laboratory of Oncology and Experimental Surgery, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. |
| authorships[8].author.id | https://openalex.org/A5048432907 |
| authorships[8].author.orcid | https://orcid.org/0000-0001-5051-231X |
| authorships[8].author.display_name | Fabrice Journé |
| authorships[8].countries | BE |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I132053463, https://openalex.org/I2801838318 |
| authorships[8].affiliations[0].raw_affiliation_string | 1Laboratory of Oncology and Experimental Surgery, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. |
| authorships[8].institutions[0].id | https://openalex.org/I2801838318 |
| authorships[8].institutions[0].ror | https://ror.org/05e8s8534 |
| authorships[8].institutions[0].type | healthcare |
| authorships[8].institutions[0].lineage | https://openalex.org/I2801838318 |
| authorships[8].institutions[0].country_code | BE |
| authorships[8].institutions[0].display_name | Institut Jules Bordet |
| authorships[8].institutions[1].id | https://openalex.org/I132053463 |
| authorships[8].institutions[1].ror | https://ror.org/01r9htc13 |
| authorships[8].institutions[1].type | education |
| authorships[8].institutions[1].lineage | https://openalex.org/I132053463 |
| authorships[8].institutions[1].country_code | BE |
| authorships[8].institutions[1].display_name | Université Libre de Bruxelles |
| authorships[8].author_position | last |
| authorships[8].raw_author_name | Fabrice Journe |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | 1Laboratory of Oncology and Experimental Surgery, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://aacrjournals.org/mcr/article-pdf/19/7/1221/3058268/1221.pdf |
| open_access.oa_status | bronze |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Dasatinib Stimulates Its Own Mechanism of Resistance by Activating a CRTC3/MITF/Bcl-2 Pathway in Melanoma with Mutant or Amplified c-Kit |
| has_fulltext | True |
| is_retracted | False |
| updated_date | 2025-11-23T05:10:03.516525 |
| primary_topic.id | https://openalex.org/T11346 |
| primary_topic.field.id | https://openalex.org/fields/24 |
| primary_topic.field.display_name | Immunology and Microbiology |
| primary_topic.score | 0.9997000098228455 |
| primary_topic.domain.id | https://openalex.org/domains/1 |
| primary_topic.domain.display_name | Life Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2403 |
| primary_topic.subfield.display_name | Immunology |
| primary_topic.display_name | Mast cells and histamine |
| related_works | https://openalex.org/W2110517464, https://openalex.org/W1595732636, https://openalex.org/W2000371206, https://openalex.org/W4281715147, https://openalex.org/W2062767635, https://openalex.org/W2996746845, https://openalex.org/W50195066, https://openalex.org/W2012090029, https://openalex.org/W4327614332, https://openalex.org/W2038169799 |
| cited_by_count | 6 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 2 |
| counts_by_year[1].year | 2023 |
| counts_by_year[1].cited_by_count | 2 |
| counts_by_year[2].year | 2022 |
| counts_by_year[2].cited_by_count | 2 |
| locations_count | 3 |
| best_oa_location.id | doi:10.1158/1541-7786.mcr-20-1040 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S192067876 |
| best_oa_location.source.issn | 1541-7786, 1557-3125 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | 1541-7786 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | Molecular Cancer Research |
| best_oa_location.source.host_organization | https://openalex.org/P4310320273 |
| best_oa_location.source.host_organization_name | American Association for Cancer Research |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320273 |
| best_oa_location.license | |
| best_oa_location.pdf_url | https://aacrjournals.org/mcr/article-pdf/19/7/1221/3058268/1221.pdf |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Molecular Cancer Research |
| best_oa_location.landing_page_url | https://doi.org/10.1158/1541-7786.mcr-20-1040 |
| primary_location.id | doi:10.1158/1541-7786.mcr-20-1040 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S192067876 |
| primary_location.source.issn | 1541-7786, 1557-3125 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 1541-7786 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Molecular Cancer Research |
| primary_location.source.host_organization | https://openalex.org/P4310320273 |
| primary_location.source.host_organization_name | American Association for Cancer Research |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320273 |
| primary_location.license | |
| primary_location.pdf_url | https://aacrjournals.org/mcr/article-pdf/19/7/1221/3058268/1221.pdf |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Molecular Cancer Research |
| primary_location.landing_page_url | https://doi.org/10.1158/1541-7786.mcr-20-1040 |
| publication_date | 2021-03-19 |
| publication_year | 2021 |
| referenced_works | https://openalex.org/W2945009392, https://openalex.org/W3007219438, https://openalex.org/W3020931570, https://openalex.org/W6776454741, https://openalex.org/W2309118970, https://openalex.org/W2099200814, https://openalex.org/W2027563354, https://openalex.org/W4211076773, https://openalex.org/W1991541715, https://openalex.org/W1988698939, https://openalex.org/W2137020485, https://openalex.org/W6959105251, https://openalex.org/W2063346434, https://openalex.org/W6690414926, https://openalex.org/W2031510245, https://openalex.org/W2564638997, https://openalex.org/W2159360580, https://openalex.org/W2599316103, https://openalex.org/W1487917997, https://openalex.org/W2162997202, https://openalex.org/W7075995619, https://openalex.org/W2508313158, https://openalex.org/W2002918515, https://openalex.org/W2888508916, https://openalex.org/W2884960998, https://openalex.org/W2331048077, https://openalex.org/W1998186535, https://openalex.org/W2075240818, https://openalex.org/W2300290254, https://openalex.org/W2737216197, https://openalex.org/W2051718122, https://openalex.org/W1994027154, https://openalex.org/W3046906716, https://openalex.org/W2096223992, https://openalex.org/W2063055656, https://openalex.org/W2143060756, https://openalex.org/W1982714302, https://openalex.org/W2592824004, https://openalex.org/W1883936019, https://openalex.org/W6602529667, https://openalex.org/W2080444173, https://openalex.org/W2148558691, https://openalex.org/W2065989662, https://openalex.org/W1967834264, https://openalex.org/W2591748434, https://openalex.org/W2171202246, https://openalex.org/W2111118397, https://openalex.org/W2112468133, https://openalex.org/W2145824104, https://openalex.org/W2147474070, https://openalex.org/W2749731631, https://openalex.org/W2626256779, https://openalex.org/W1553954185, https://openalex.org/W2773849864, https://openalex.org/W2081379689, https://openalex.org/W60508422 |
| referenced_works_count | 56 |
| abstract_inverted_index.a | 8, 46 |
| abstract_inverted_index.In | 197 |
| abstract_inverted_index.We | 55, 88 |
| abstract_inverted_index.an | 104 |
| abstract_inverted_index.as | 45, 150, 152 |
| abstract_inverted_index.at | 77, 233 |
| abstract_inverted_index.be | 83 |
| abstract_inverted_index.by | 136, 169 |
| abstract_inverted_index.in | 15, 49, 85, 106, 190, 207, 246, 268 |
| abstract_inverted_index.is | 24, 62 |
| abstract_inverted_index.of | 5, 39, 98, 123, 143, 148, 156, 177, 185, 193, 213, 216, 244, 256 |
| abstract_inverted_index.on | 118 |
| abstract_inverted_index.or | 2, 171 |
| abstract_inverted_index.to | 29, 32, 60, 64, 162, 180, 195, 224 |
| abstract_inverted_index.we | 73, 199 |
| abstract_inverted_index.all | 163 |
| abstract_inverted_index.and | 17, 36, 94, 100, 108, 130, 187, 218 |
| abstract_inverted_index.are | 7 |
| abstract_inverted_index.but | 103, 228 |
| abstract_inverted_index.can | 81 |
| abstract_inverted_index.due | 28 |
| abstract_inverted_index.for | 201 |
| abstract_inverted_index.its | 30, 43, 109, 210, 253, 264 |
| abstract_inverted_index.may | 238, 262 |
| abstract_inverted_index.the | 25, 40, 119, 175, 183, 191, 202, 240 |
| abstract_inverted_index.use | 44 |
| abstract_inverted_index.CREB | 120, 140 |
| abstract_inverted_index.MAPK | 99, 217 |
| abstract_inverted_index.MITF | 107, 129, 145, 157, 186 |
| abstract_inverted_index.More | 125 |
| abstract_inverted_index.SIK2 | 133 |
| abstract_inverted_index.axis | 189 |
| abstract_inverted_index.bind | 33 |
| abstract_inverted_index.both | 34 |
| abstract_inverted_index.but, | 71 |
| abstract_inverted_index.cell | 66 |
| abstract_inverted_index.most | 26 |
| abstract_inverted_index.that | 58, 80, 205 |
| abstract_inverted_index.then | 89 |
| abstract_inverted_index.time | 204 |
| abstract_inverted_index.turn | 117 |
| abstract_inverted_index.weak | 241 |
| abstract_inverted_index.well | 151 |
| abstract_inverted_index.with | 248, 270 |
| abstract_inverted_index.Among | 20 |
| abstract_inverted_index.Bcl-2 | 112, 131, 149, 167, 172, 188 |
| abstract_inverted_index.CRTC3 | 114, 137 |
| abstract_inverted_index.MITF, | 144 |
| abstract_inverted_index.MITF. | 124 |
| abstract_inverted_index.acral | 16 |
| abstract_inverted_index.agent | 48 |
| abstract_inverted_index.c-Kit | 6, 21, 69, 226 |
| abstract_inverted_index.cells | 160, 179 |
| abstract_inverted_index.doses | 236 |
| abstract_inverted_index.first | 56, 203 |
| abstract_inverted_index.found | 57, 84, 95 |
| abstract_inverted_index.lines | 67 |
| abstract_inverted_index.lower | 75 |
| abstract_inverted_index.which | 12, 116, 237, 261 |
| abstract_inverted_index.active | 27, 35 |
| abstract_inverted_index.blood. | 87 |
| abstract_inverted_index.effect | 76 |
| abstract_inverted_index.higher | 78 |
| abstract_inverted_index.modest | 265 |
| abstract_inverted_index.occurs | 13 |
| abstract_inverted_index.proper | 211, 254 |
| abstract_inverted_index.showed | 51, 200 |
| abstract_inverted_index.single | 47 |
| abstract_inverted_index.target | 111 |
| abstract_inverted_index.ABT-199 | 170 |
| abstract_inverted_index.ability | 31 |
| abstract_inverted_index.benefit | 243 |
| abstract_inverted_index.explain | 239, 263 |
| abstract_inverted_index.limited | 52 |
| abstract_inverted_index.mucosal | 18 |
| abstract_inverted_index.pathway | 92, 231 |
| abstract_inverted_index.patient | 86 |
| abstract_inverted_index.readily | 82 |
| abstract_inverted_index.reduced | 138 |
| abstract_inverted_index.renders | 158 |
| abstract_inverted_index.through | 113, 132, 229, 258 |
| abstract_inverted_index.Abstract | 0 |
| abstract_inverted_index.However, | 42 |
| abstract_inverted_index.PI3K/AKT | 101, 219 |
| abstract_inverted_index.benefit. | 54 |
| abstract_inverted_index.clinical | 53, 242, 266 |
| abstract_inverted_index.commonly | 14, 222 |
| abstract_inverted_index.complete | 96 |
| abstract_inverted_index.frequent | 9 |
| abstract_inverted_index.inactive | 37 |
| abstract_inverted_index.increase | 105 |
| abstract_inverted_index.knockout | 173 |
| abstract_inverted_index.melanoma | 50, 65, 159, 178, 194, 208 |
| abstract_inverted_index.observed | 74 |
| abstract_inverted_index.pathway, | 115, 260 |
| abstract_inverted_index.pathways | 102, 220 |
| abstract_inverted_index.patients | 247, 269 |
| abstract_inverted_index.relevant | 91, 235 |
| abstract_inverted_index.restores | 174 |
| abstract_inverted_index.revealed | 135 |
| abstract_inverted_index.Dasatinib | 251 |
| abstract_inverted_index.Selective | 166 |
| abstract_inverted_index.dasatinib | 23, 61, 127, 164, 206, 245 |
| abstract_inverted_index.harboring | 68 |
| abstract_inverted_index.mechanism | 212, 255 |
| abstract_inverted_index.melanoma. | 19, 249, 271 |
| abstract_inverted_index.mutations | 4 |
| abstract_inverted_index.oncogenic | 10 |
| abstract_inverted_index.receptor. | 41 |
| abstract_inverted_index.regulated | 121 |
| abstract_inverted_index.resistant | 161 |
| abstract_inverted_index.secondary | 225 |
| abstract_inverted_index.activating | 3 |
| abstract_inverted_index.activation | 142, 147, 232 |
| abstract_inverted_index.alteration | 70 |
| abstract_inverted_index.associated | 223 |
| abstract_inverted_index.clinically | 234 |
| abstract_inverted_index.dasatinib, | 181 |
| abstract_inverted_index.dasatinib. | 196 |
| abstract_inverted_index.downstream | 110 |
| abstract_inverted_index.efficiency | 267 |
| abstract_inverted_index.inhibition | 97, 134, 168 |
| abstract_inverted_index.mutations, | 227 |
| abstract_inverted_index.resistance | 192, 257 |
| abstract_inverted_index.restricted | 63 |
| abstract_inverted_index.stimulates | 209, 252 |
| abstract_inverted_index.validating | 182 |
| abstract_inverted_index.alteration, | 11 |
| abstract_inverted_index.alterations | 93 |
| abstract_inverted_index.conclusion, | 198 |
| abstract_inverted_index.inhibitors, | 22 |
| abstract_inverted_index.involvement | 184 |
| abstract_inverted_index.resistance, | 214 |
| abstract_inverted_index.sensitivity | 59, 176 |
| abstract_inverted_index.upregulates | 128 |
| abstract_inverted_index.Furthermore, | 154 |
| abstract_inverted_index.importantly, | 126 |
| abstract_inverted_index.investigated | 90 |
| abstract_inverted_index.reactivation | 221 |
| abstract_inverted_index.Amplification | 1 |
| abstract_inverted_index.Implications: | 250 |
| abstract_inverted_index.conformations | 38 |
| abstract_inverted_index.independently | 215 |
| abstract_inverted_index.pigmentation. | 153 |
| abstract_inverted_index.transcription | 122, 141, 146 |
| abstract_inverted_index.unexpectedly, | 72 |
| abstract_inverted_index.concentrations | 79 |
| abstract_inverted_index.overexpression | 155 |
| abstract_inverted_index.concentrations. | 165 |
| abstract_inverted_index.CRTC3/MITF/Bcl-2 | 230, 259 |
| abstract_inverted_index.phosphorylation, | 139 |
| cited_by_percentile_year.max | 97 |
| cited_by_percentile_year.min | 94 |
| corresponding_author_ids | https://openalex.org/A5017607911 |
| countries_distinct_count | 2 |
| institutions_distinct_count | 9 |
| corresponding_institution_ids | https://openalex.org/I132053463, https://openalex.org/I2801838318 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.4699999988079071 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.54306728 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |